This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1917)
- Annex to CHMP highlights(367)
- Annual Report(94)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1983)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2712)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(141)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Overview(1978)
- EPAR - Paediatric investigation plan compliance statement(89)
- EPAR - Procedural steps taken and scientific information after authorisation(1888)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1978)
- EPAR - Public assessment report(1553)
- EPAR - Risk-management-plan summary(1146)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(189)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(72)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(804)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(459)
- Medicines under additional monitoring(24)
- Minutes(1251)
- Newsletter(300)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4063)
- Overview of comments(331)
- Parallel distribution(1)
- Periodic safety update single assessment(2763)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5497)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5308)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(27)
- Recruitment(38)
- Referrals document(2782)
- Regulatory and procedural guideline(723)
- Report(1621)
- Scientific guideline(2466)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1230)
- Summary of opinion - Initial authorisation(1689)
- Supply shortage(59)
- Template or form(482)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- Advanced therapies(1797)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(656)
- Brexit(121)
- Careers(6)
- Clinical trials(604)
- Compassionate use(16)
- Compliance and inspections(600)
- Corporate(117)
- COVID-19(898)
- Data on medicines(942)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2190)
- Governance(708)
- Innovation(1164)
- Maximum residue limit(1002)
- Medication error(29)
- Medicines(47185)
- Medicines for use outside the EU(148)
- Medicine shortages(303)
- Mpox(39)
- Paediatrics(12270)
- Parallel distribution(15)
- Pharmacovigilance(9675)
- Procurement(132)
- Product information(6320)
- Quality of medicines(224)
- Rare diseases(8244)
- Referrals(3396)
- Regulatory and procedural guidance(3512)
- Research and development(491)
- Scientific advice(293)
- Scientific guidelines(1756)
- SME(259)
- Vaccines(1503)
- Veterinary limited markets(64)
Search results (84551)
Atazanavir Viatris (previously Atazanavir Mylan) : EPAR - All Authorised presentations
English (EN) (47.81 KB - PDF)
български (BG) (53.63 KB - PDF)
español (ES) (31.92 KB - PDF)
čeština (CS) (49.81 KB - PDF)
dansk (DA) (44.17 KB - PDF)
Deutsch (DE) (43.11 KB - PDF)
eesti keel (ET) (43.7 KB - PDF)
ελληνικά (EL) (44.02 KB - PDF)
français (FR) (15.25 KB - PDF)
hrvatski (HR) (71.34 KB - PDF)
íslenska (IS) (44.96 KB - PDF)
italiano (IT) (42.68 KB - PDF)
latviešu valoda (LV) (60.44 KB - PDF)
lietuvių kalba (LT) (63.63 KB - PDF)
magyar (HU) (62.61 KB - PDF)
Malti (MT) (34.96 KB - PDF)
Nederlands (NL) (44.65 KB - PDF)
norsk (NO) (35.61 KB - PDF)
polski (PL) (34.5 KB - PDF)
português (PT) (9.86 KB - PDF)
română (RO) (48.06 KB - PDF)
slovenčina (SK) (59.28 KB - PDF)
slovenščina (SL) (40.33 KB - PDF)
Suomi (FI) (54.37 KB - PDF)
svenska (SV) (35.22 KB - PDF)
P/0105/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M06)
English (EN) (239.5 KB - PDF)
EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.
Xarelto : EPAR - Risk-management-plan
English (EN) (2.37 MB - PDF)
Amended EU recommendations for the seasonal influenza vaccine composition for the season 2024/2025
English (EN) (187.83 KB - PDF)
2023 annual report of the European Medicines Agency
English (EN) (5.36 MB - PDF)
Circovac : EPAR - Product Information
English (EN) (81.49 KB - PDF)
български (BG) (91.78 KB - PDF)
español (ES) (81.51 KB - PDF)
čeština (CS) (92.48 KB - PDF)
dansk (DA) (82.05 KB - PDF)
Deutsch (DE) (81.72 KB - PDF)
eesti keel (ET) (81.22 KB - PDF)
ελληνικά (EL) (91.79 KB - PDF)
français (FR) (81.63 KB - PDF)
hrvatski (HR) (91.56 KB - PDF)
íslenska (IS) (81.52 KB - PDF)
Gaeilge (GA) (81.36 KB - PDF)
italiano (IT) (81.76 KB - PDF)
latviešu valoda (LV) (92.14 KB - PDF)
lietuvių kalba (LT) (92.19 KB - PDF)
magyar (HU) (92.76 KB - PDF)
Malti (MT) (93.86 KB - PDF)
Nederlands (NL) (81.15 KB - PDF)
norsk (NO) (81.52 KB - PDF)
polski (PL) (93.22 KB - PDF)
português (PT) (82.53 KB - PDF)
română (RO) (91.73 KB - PDF)
slovenčina (SK) (81.75 KB - PDF)
slovenščina (SL) (81.76 KB - PDF)
Suomi (FI) (81.11 KB - PDF)
svenska (SV) (81.47 KB - PDF)
Circovac : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (81.94 KB - PDF)